In breast [17], colorectal [18] and pancreatic cancer [19], blocking NRP-2 resulted in suppressed tumor growth, reduced lymphangiogenesis/angiogenesis and metastasis, although the underlying mechanisms are still poorly understood. The gene discussed is NRP2; the disease is neoplasm.